BioSpace News Archive

Esoteric testing is the analysis of ‘rare’ molecules or substances. It is not performed in a routine clinical laboratory.

Fact.MR: Rising incidence of bacterial infections and chronic diseases, particularly cancer has underscored the need for accurate leukocyte count testing products, creating significant opportunities for expansion.

Myovant Sciences, a healthcare company focused on redefining care for women and for men, announced the European Commission has approved the marketing authorization application for RYEQO® for the treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age, with no limitation for duration of use.

Theravance Biopharma, Inc., a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, will report its second quarter 2021 financial results and provide a business update after market close on Tuesday, August 3, 2021.

MaaT Pharma, a French clinical-stage biotech company specialized in the development of microbiome-based therapies aiming to restore the microbiome/immune system symbiosis in oncology patients, announced that its MEPA program was awarded a EURO 1.9 million grant from the Plan France Relance.

MONTREAL, July 20, 2021 /PRNewswire/ - NIMIUM Therapeutics, a Montreal-based biotech, has formed a partnership with Paraza Pharma to develop a new treatment for cardiometabolic diseases.

Mars Veterinary Health North America, part of family-owned company Mars, Incorporated, announced a $500 million multi-year commitment to create career advancement opportunities, increase workforce diversity, and offer differentiated pay and benefits by 2025.

Owens & Minor, Inc. plans to release financial results for the second quarter of 2021 on Tuesday, August 3, 2021, before trading begins on the New York Stock Exchange.

Immuneering Corporation, a private biopharmaceutical company advancing a robust pipeline of oncology and neuroscience drug candidates that are designed to uniquely disrupt cellular signaling dynamics, announced the appointment of Michael Bookman to the newly created position of General Counsel and Secretary, effective immediately.

EyePoint Pharmaceuticals, Inc., a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, announced that the Company expects to receive a nine month extension on DEXYCU®’s pass-through payment status, which otherwise would expire on March 31, 2022.